Cytokinetics, Inc.
625 articles about Cytokinetics, Inc.
-
The FDA had a fairly quiet week, approving drugs, providing clearance, greenlighting clinical trials, and other regulatory activities for Alnylam, Eli Lilly, Cytokinetics, and more.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 03, 2022
10/3/2022
Cytokinetics, Incorporated announced that on September 30, 2022 it granted stock options to purchase an aggregate of 99,000 shares of common stock to 10 new employees, whose employment commenced in September 2022, as a material inducement to their employment.
-
Scandion Oncology, Edesa, Clovis, Lexicon and Cytokinetics share a string of positive news from their clinical trials on heart failure, cancer, COVID-19 and ARDS.
-
Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting
10/2/2022
Cytokinetics, Incorporated announced new data on symptom improvement and quality of life related to treatment with aficamten in REDWOOD-HCM OLE in a Late Breaking Clinical Trials session at the Heart Failure Society of America Annual Scientific Meeting in Washington, D.C.
-
Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessions
9/30/2022
Cytokinetics, Incorporated presented new data on the reduction and withdrawal of background standard of care medical therapy in patients treated with aficamten in REDWOOD-HCM OLE in a Late Breaking Clinical Trials session at the 2022 HCM Society Scientific Sessions, the inaugural scientific sessions of this newly launched professional medical society, held in National Harbor, MD.
-
Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program
9/28/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the fifth annual Cytokinetics Communications Grant Program.
-
Cytokinetics Announces Upcoming Presentations at the 2022 Inaugural HCM Society Scientific Sessions and the HFSA Annual Scientific Meeting
9/26/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced six upcoming presentations, including two presentations at the 2022 Inaugural HCM Society Scientific Sessions.
-
Cytokinetics to Participate in Upcoming September 2022 Investor Conferences
9/6/2022
Cytokinetics, Incorporated announced that the company is scheduled to participate in the following investor conferences.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 01, 2022
9/1/2022
Cytokinetics, Incorporated announced that on August 31, 2022 it granted stock options to purchase an aggregate of 186,400 shares of common stock to 23 new employees, whose employment commenced in August 2022, as a material inducement to their employment.
-
Cytokinetics Reports Second Quarter 2022 Financial Results
8/4/2022
Cytokinetics, Incorporated reported financial results for the second quarter of 2022. Net loss for the second quarter was $19.8 million, or $0.23 per share, compared to net loss for the second quarter of 2021 of $61.6 million, or $0.86 per share.
-
Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics’ Completed ALS Clinical Trials
8/4/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced a new release of the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database updated with clinical data from Cytokinetics’ completed clinical trials in ALS including, BENEFIT-ALS.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 01, 2022
8/1/2022
Cytokinetics, Incorporated announced that on July 29, 2022 it granted stock options to purchase an aggregate of 88,200 shares of common stock to 11 new employees, whose employment commenced in July 2022, as a material inducement to their employment.
-
Cytokinetics to Announce Second Quarter Results on August 4, 2022
7/21/2022
Cytokinetics, Incorporated announced that it is scheduled to report second quarter results on August 4, 2022 at 4:00 PM Eastern Time.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - July 05, 2022
7/5/2022
Cytokinetics, Incorporated announced that on June 30, 2022 it granted stock options to purchase an aggregate of 180,450 shares of common stock to 19 new employees, whose employment commenced in June 2022, as a material inducement to their employment.
-
Cytokinetics Announces Pricing of $450 Million Convertible Senior Notes Offering
7/1/2022
Cytokinetics, Incorporated announced the pricing of its offering of $450.0 million aggregate principal amount of 3.50% convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
Cytokinetics Announces Proposed Convertible Senior Notes Offering - June 29, 2022
6/29/2022
Cytokinetics, Incorporated announced its intention to offer, subject to market and other conditions, $450.0 million aggregate principal amount of convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
Cytokinetics Announces Date for FDA Advisory Committee Meeting to Review New Drug Application for Omecamtiv Mecarbil
6/24/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has informed the company that the previously announced meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the New Drug Application for omecamtiv mecarbil is currently scheduled for December 13, 2022.
-
Cytokinetics Provides Regulatory Update for Omecamtiv MecarbilRecent Company Submission in Response to FDA Request Extends PDUFA Date
6/17/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that, in response to a request from the U.S. Food and Drug Administration (FDA), the company recently provided additional pharmacokinetic analyses of omecamtiv mecarbil related to the company’s new drug application (NDA).
-
Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALSManaged Access Program for People Who Have Completed Prior Cytokinetics ALS Trials to Begin in 2H 2022
6/16/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the start of COURAGE-ALS OLE an open-label extension clinical study designed to assess the long-term safety and tolerability of reldesemtiv in people with amyotrophic lateral sclerosis (ALS).
-
Cytokinetics Announces Additional Data From REDWOOD-HCM Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
6/13/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from a new analysis of REDWOOD-HCM at the American Society of Echocardiography (ASE) 33rd Annual Scientific Sessions.